Biossil Inc. Deal History & Licensing Activity
Biossil Inc. is a biotech. Over the past three years, Biossil Inc. has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (3 deals). The company currently has 2 active clinical trials, primarily in Rare Disease.
Deals (12mo)
2
Active Trials
2
Top Modality
Small Molecules
Focus Area
Rare Disease
Biossil Inc. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Biossil Inc. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| odiparcil | Biossil, Inc. | Small Molecules | Phase 2 | acquisition | Dec 31, 2025 |
Biossil Inc. Pipeline Focus
Therapeutic areas and modalities where Biossil Inc. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Biossil Inc. Clinical Pipeline
Biossil Inc. has 2 active clinical trials across 2 development phases.
1
Unknown
1
Phase 2
See How Your Asset Matches Biossil Inc.'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Biossil Inc. Licensing & Deal Activity
Biossil Inc. is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Biossil Inc. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Biossil Inc. include Rare Disease (2 deals and trials), Rare Disease (2 deals and trials), and Oncology (1 deal and trial). In terms of modality, Biossil Inc. has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Biossil Inc. and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Biossil Inc.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.